Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Jul 25;8(7):e68940. doi: 10.1371/journal.pone.0068940

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 Joice, Lipsitch

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.

PMC Copyright notice

a, SIR model with a proportion of the population as vaccinated susceptibles ( subscript) and as unvaccinated susceptibles ( subscript), who can get infected with either the drug-sensitive ( superscript) or –resistant ( superscript) strains, get treated ( superscript) or not ( superscript) and are removed due to recovery or death (). This is the model of Ref. [2], modified to include vaccination. b, Model evaluations for final cumulative proportion resistant among all infections over the course of one season, as a function of the additional vaccine efficacy against resistant, compared to sensitive strains (x-axis) and the fraction of influenza infections treated (y-axis). Here, vaccine coverage is 40% and = 59%.

Inline graphic — a, SIR model with a proportion of the population as vaccinated susceptibles ( subscript) and as unvaccinated susceptibles ( subscript), who can get infected with either the drug-sensitive ( superscript) or –resistant ( superscript) strains, get treated ( superscript) or not ( superscript) and are removed due to recovery or death (). This is the model of Ref. [2], modified to include vaccination. b, Model evaluations for final cumulative proportion resistant among all infections over the course of one season, as a function of the additional vaccine efficacy against resistant, compared to sensitive strains (x-axis) and the fraction of influenza infections treated (y-axis). Here, vaccine coverage is 40% and = 59%.